Hemispherx Biopharma (HEB) Reports Q2 Loss of $0.04/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/5/2026
- Nasdaq eyes lower open after midterms-fueled surge as chip, data center stocks fall
- Massive market rotation raises question: Is the sell-AI trade here to stay?
- Goldman sees major AI and data center policy implications from ‘blue tsunami’
- Apple seeks to raise up to $7 billion in seven-tranche bond offering
- Nvidia chips stockpile in Hong Kong awaits China import approval - report
Tweet
Share
E-mailGet Alerts HEB Hot Sheet
Price: $1.80 --0%
Financial Fact:
Basic and diluted loss per share (Note 2): -0.01
Today's EPS Names:
KELYA, ROX, KEEL, More
Financial Fact:
Basic and diluted loss per share (Note 2): -0.01
Today's EPS Names:
KELYA, ROX, KEEL, More
Join SI Premium – FREE
Hemispherx Biopharma (NYSE: HEB) reported Q2 EPS of ($0.04), versus ($0.05) reported last year.
For earnings history and earnings-related data on Hemispherx Biopharma (HEB) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Becton Dickinson (BDX) Tops Q4 EPS by 8c; Offers Guidance
- VisionChina (VISN) Tops Q3 EPS by 1c
- DXP Enterprises (DXPE) Misses Q3 EPS by 1c
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
